Brief: JCR Pharmaceuticals Announces Approval Of IZCARGO In Japan
23/03/2021 11:39
March 23 (Reuters) - JCR Pharmaceuticals Co Ltd 4552.T :
* JCR PHARMACEUTICALS ANNOUNCES APPROVAL OF IZCARGO®
(PABINAFUSP
ALFA) FOR TREATMENT OF MPS II (HUNTER SYNDROME) IN JAPAN
Source text for Eikon: ID:nBw1DpHqha
Further company coverage: 4552.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results